Catalyst Wire Dossier Catalyst Wire Dossier
EMA approval · 2026-04-28

EMA Authorised: Vfend (voriconazole) — Pfizer Europe MA EEIG

View source ↗

Summary

European Medicines Agency authorises Vfend (voriconazole) for fungal infections including candidiasis, mycoses, and aspergillosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VFEND (Voriconazole)

Snippet

Status: Authorised. Therapeutic area: Candidiasis;Mycoses;Aspergillosis. MAH: Pfizer Europe MA EEIG. Decision date: 10/02/2026